相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J. Boeree et al.
LANCET INFECTIOUS DISEASES (2017)
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model
Yanmin Hu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
Martin J. Boeree et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Exposure to Total and Protein-Unbound Rifampin Is Not Affected by Malnutrition in Indonesian Tuberculosis Patients
L. H. M. te Brake et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo
Yanmin Hu et al.
FRONTIERS IN MICROBIOLOGY (2015)
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Stephen H. Gillespie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
Amina Jindani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Optimization of the Rifampin Dosage to Improve the Therapeutic Efficacy in Tuberculosis Treatment Using a Murine Model
Jurriaan E. M. de Steenwinkel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis
Ian M. Rosenthal et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
Jakko van Ingen et al.
CLINICAL INFECTIOUS DISEASES (2011)
Resuscitation-promoting Factors Reveal an Occult Population of Tubercle Bacilli in Sputum
Galina V. Mukamolova et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
The near future: Improving the activity of rifamycins and pyrazinamide
D. A. Mitchison et al.
TUBERCULOSIS (2010)
Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears
A. H. Diacon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Antituberculosis drugs and hepatotoxicity
Wing Wai Yew et al.
RESPIROLOGY (2006)
Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin
AK Meagher et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Population pharmacokinetics II: Estimation methods
EI Ette et al.
ANNALS OF PHARMACOTHERAPY (2004)
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis
R Jayaram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide
YM Hu et al.
JOURNAL OF BACTERIOLOGY (2000)
分享论文
